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We describe noncovalent, reversible asparagine ethylenediamine
(AsnEDA) inhibitors of the Plasmodium falciparum proteasome
(Pf20S) β5 subunit that spare all active subunits of human consti-
tutive and immuno-proteasomes. The compounds are active
against erythrocytic, sexual, and liver-stage parasites, against par-
asites resistant to current antimalarials, and against P. falciparum
strains from patients in Africa. The β5 inhibitors synergize with a
β2 inhibitor in vitro and in mice and with artemisinin. P. falciparum
selected for resistance to an AsnEDA β5 inhibitor surprisingly har-
bored a point mutation in the noncatalytic β6 subunit. The β6 mu-
tant was resistant to the species-selective Pf20S β5 inhibitor but
remained sensitive to the species-nonselective β5 inhibitors borte-
zomib and carfilzomib. Moreover, resistance to the Pf20S β5 inhibitor
was accompanied by increased sensitivity to a Pf20S β2 inhibitor. Fi-
nally, the β5 inhibitor-resistant mutant had a fitness cost that was
exacerbated by irradiation. Thus, used in combination, multistage-
active inhibitors of the Pf20S β5 and β2 subunits afford synergistic
antimalarial activity with a potential to delay the emergence of re-
sistance to artemisinins and each other.
Plasmodium | malaria | proteasome inhibitors | artemisinin |
collateral sensitivity
Each year malaria causes an estimated 200 million cases andnearly 500,000 deaths in children under 5 y of age, with the
large majority of serious illnesses and deaths due to Plasmodium
falciparum (1). Resistance to older antimalarials, such as chloro-
quine, is common, and resistance to the most effective newer
treatments, artemisinin-based combination therapies (ACTs), is
established in Southeast Asia (2–4). Compounds that target the
preerythrocytic hepatic stage and block the development of the
transmissible gametocyte form that are taken up by the mosquito
are ideal candidates for malaria prevention, but few antimalarials
are effective against these stages. The growing threat of ACT
failure and the need to target nonerythrocytic stages underscore
the need for drugs with new targets in the parasite.
Proteasome inhibitors have the potential to fulfill both re-
quirements (5), and the proteasome has emerged as an important
target for antimalarial drug development (6–10). Eukaryotic pro-
teasomes have two copies of each of the three proteolytically ac-
tive subunits—chymotryptic β5, tryptic β2, and caspase-like β1—in
each 20S core particle. Several proteasome inhibitors are effective
in vitro against Plasmodium spp. at multiple stages of the parasite
lifecycle, including the erythrocytic, liver, and gametocyte stages,
and for the treatment of Plasmodium berghei-infected mice (9, 11–
15). The human host has two major isoforms of the 20S, consti-
tutive proteasomes (c-20S) and immunoproteasomes (i-20S), with
subtle but significant differences in proteolytic activity and
functions. Proteasomes are important in all human cells. Inhibition
of c-20S is cytotoxic, and inhibition of i-20S can dampen im-
mune responses against infection (16, 17). Proteasome inhibitors
designed to treat infections must achieve a high degree of species
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selectivity to avoid toxicity and impairment of the host’s immune
response.
Developing pathogen-selective proteasome inhibitors that spare
both i-20S and c-20S has been challenging, as proteasome subunits
are highly conserved. Species-selective proteasome inhibitors were
first reported for Mycobacterium tuberculosis (18, 19) and then
for Plasmodium sp (6, 10), trypanosomes and Leishmania (20).
However, most studies confined assessment of selectivity to
testing the impact of these compounds on host c-20S, whereas i-
20S inhibition was not examined. Moreover, most studies tested
activity against only one of the human proteasome subunits.
Here we present a class of proteasome inhibitors that is highly
species-selective for the Pf20S β5 subunit over all active subunits of
both human c-20S and i-20S. Use of these inhibitors revealed three
previously unreported findings with Pf20S inhibition: late-stage
gametocytocidal activity and inhibition of gamete activation;
marked synergy between a Pf20S β5 inhibitor and a β2 inhibitor;
and association of resistance to a Pf20S β5 inhibitor with markedly
increased sensitivity to inhibition of β2. The findings of synergy and
collateral sensitivity suggest the potential value of capitalizing on
interactions among different subunits of the parasite proteasome.
Results
Identification of Antimalarial Asparagine Ethylenediamines. A focused
proteasome inhibitor library of around 180 compounds including
three unique classes was synthesized in-house (18, 19, 21–24). We
randomly selected 95 of these compounds at 10 μM with bortezo-
mib, a pan-proteasome inhibitor, serving as a positive control (Fig.
1A). Initial screens measured the ability of the compound to inhibit
hydrolysis of a fluorogenic chymotryptic substrate, suc-Leu-Leu-
Val-Tyr (LLVY)-AMC, by a P. falciparum lysate. We focused
further on compounds that afforded >85% inhibition of suc-
LLVY-AMC hydrolysis, comparable to the impact of bortezomib.
We next tested compounds against the erythrocytic stage of the
parasite using a standard in vitro growth inhibition assay over 72 h
(Fig. 1D) (25). Compounds in classes of N,C-capped dipeptides
(22) and β-amino acid dipeptidomimetics (23) were potent against
P. falciparum but were also potent inhibitors of i-20S and hence
were not sufficiently species selective. We next focused on com-
pounds belonging to a recently reported class of proteasome in-
hibitors, the asparagine ethylenediamines (AsnEDAs) (17). Among
these, PKS3080 and PKS21004 showed the most potent antima-
larial activity (Fig. 1A and SI Appendix, Table S1). PKS21003, a
regioisomer of PKS21004, was inactive against the parasite and
served as a negative control.
We assessed subunit selectivity with the activity-based protea-
some probe MV151, a fluorescent vinyl sulfone that irreversibly
labels the three catalytic subunits of the parasite proteasome (7,
26). PKS21004 and bortezomib specifically inhibited labeling of
Pf20S β5, whereas PKS21003 did not (Fig. 1B, Upper). In contrast,
PKS21004 did not block MV151 from labeling Pf20S β2 or β1.
Importantly, none of the AsnEDAs showed appreciable inhibitory
activity against the human c-20S subunits β1c or β2c or the i-20S
subunits β1i or β2i (17). In contrast, in our assay, Trp-Leu-Trp-vinyl
sulfone (WLW-VS) (6), reported to be highly selective for Pf20S
β2 over human c-20S β2c and human i-20S β2i, was highly potent
against human c-20S β5c and human i-20S β5i, with IC50s of
100 nM and 23 nM, respectively (SI Appendix, Fig. S1). Thus, it is
important to confirm species selectivity by testing all proteasome
subunits, as inhibitors intended for one subunit of one species can
inhibit different subunits of a different species.
The ability of PKS21004 to block the covalent reaction with
Pf20S β5 and MV151 was dose-dependent (Fig. 1B, Lower). Poly-
ubiquitinylated proteins accumulated in P. falciparum (Pf3D7 strain)
in vitro within 4 h of exposure to 1 μM PKS21004, similar to results
with 10 μM bortezomib (Fig. 1C).
We tested the cytotoxicity of PKS21004 and PKS21003 against
the human hepatoma cell line HepG2, which predominantly ex-
presses c-20S, the human lymphoma cell line Karpas 1106P, which
predominantly expresses i-20S, and primary mouse bone marrow-
derived macrophages (MBM), which also express i-20S.
PKS21004 was selectively toxic for P. falciparum over the mam-
malian cells, while PKS21003 was nontoxic for both P. falciparum
and mammalian cells (Fig. 1D and SI Appendix, Table S1).
Docking and Structure–Activity Relationship Studies to Improve Species
Selectivity. To guide structure–activity (SAR) studies, we modeled
the binding mode of PKS21004 in Pf20S, based on the recently
solved cryo-electron microscopy structure of PKS21004 bound to i-
20S (17). Given the high sequence and structural similarity between
human i-20S and Pf20S for the relevant β5 and β6 subunits (∼60%
sequence similarity and ∼1.1-Å rmsd for the dimers’ Cαs), we
predicted that the binding mode of PKS21004 in Pf20S would be
similar to that in i-20S. In i-20S β5iβ6 (Fig. 2A), the biphenyl moiety
of PKS21004 binds to the S1 pocket and S1 side pocket, while the
Asn(t-butyl) binds to the S3 pocket, forming hydrogen bonds with
Ser27 and Ser129 of β5i. N-capped phenylpropionate of the in-
hibitor binds to S4, a solvent-exposed pocket formed by amino acid
residues of β6 (17). In Pf20S β5β6, PKS21004 is predicted to form
very similar interactions with the S1, S3, and S4 pockets (Fig. 2B and
SI Appendix, Fig. S2).
Using this model, we conducted SAR studies and developed
the species-selective Pf20S inhibitors PKS21224 and PKS21287
(Fig. 2C) by replacing the biphenyl of PKS21004 with hetero-
aromatic rings (PKS21208 and PKS21229) and by replacing the
tosyl with a hydrophilic isoxazolyl carboxamide. Both compounds
were highly potent and modestly selective for Pf20S over c-20S
and i-20S (Fig. 2F). All compounds were highly active against P.
falciparum and selective against parasite versus HepG2 cells.
PKS21224 and PKS21287, which both have lower logD (the log
of the partition of a chemical compound between the lipid and
aqueous phases) than PKS21004, were the least active against i-
20S and c-20S but were highly potent against P. falciparum, with
EC50s of 9 nM and 34 nM, respectively. However, PKS21287 had
poor cell permeability in a parallel artificial membrane perme-
ability assay (SI Appendix, Table S2). We therefore modified the
pyrazole moiety by changing the C–C linker to a C–N linker,
Fig. 1. Identification of AsnEDA Pf20S inhibitors and their characterization.
(A) Screening cascade to identify PKS3080, 21004, and the inactive congener
PKS21003. (B) Inhibition of P. falciparum cell-free lysates by PKS21004 and
bortezomib (BTZ), and dose-dependent inhibition by PKS21004 as assessed
by activity-based probe MV151. (C) PKS21004-dependent accumulation of
polyubiquinated proteins in parasites. (D) Growth inhibition of PKS21004
against three P. falciparum strains and cytotoxicity against three types of
mammalian cells; data shown are the average of three independent ex-
periments, each performed in triplicate.
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resulting in TDI4258. PKS21287 and TDI4258 showed compa-
rable IC50s against c-20S and i-20S and EC50s against P. falci-
parum 3D7 (Fig. 2F). The logD of TDI4258 at pH 7.4 (1.85) was
greater than that of PKS21287 (1.49). The change was associated
with an improvement in permeability from an undetectable level
for PKS21287 to 64 nm/s at pH 7.4 and 56 nm/s at pH 5.0 for
TDI4258. However, only 2.3% of an orally administered dose of
TDI4258 was bioavailable. Consistent with their reduced inhibitory
activity against human proteasomes, PKS21224, PKS21287, and
TDI4258 were much less cytotoxic to mammalian cells than
PKS21004 and PKS21221 (Fig. 2F). As expected, PKS21221
and TDI4258 dose-dependently blocked the labeling of Pf20S
β5 by MV151 (Fig. 2D).
Determination of IC50s Against Pf20S β5. Using purified Pf20S, we
observed that hydrolysis of substrate suc-LLVY-AMC was re-
duced by 20–30% in the presence of the β5-specific inhibitors
PKS21004, PKS21221, or TDI4258 at 10 μM and by 50% by
the β2-specific inhibitor WLW-VS at 0.5 μM (Fig. 2E) (6).
This suggested that both β2 and β5 of the Pf20S can hydrolyze
Fig. 2. AsnEDAs with improved potency and selectivity. (A and B) Binding mode of PKS21004 in the i-20S structure (17) (A) and in Pf20S (B) predicted by
docking. Only β5 and β6 are shown. Key amino acid residues involved in ligand binding are labeled in the respective enzymes. (C) Structures of AsnEDAs. (D)
Dose-dependent inhibition of Pf20S by PKS21221 and by TDI4258 assessed by the activity-based probe MV151. (E) LLVY-AMC hydrolysis by Pf20S was assessed
in the presence of AsnEDAs and WLW-VS, both separately and in combination. (F) IC50s of all AsnEDAs against human i-20S, c-20S, and Pf20S and EC50s against
P. falciparum 3D7 and HepG2. All data are averages of at least three independent experiments.
Kirkman et al. PNAS | vol. 115 | no. 29 | E6865
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suc-LLVY-AMC. The combination of WLW-VS at 0.5 μM and
any of the AsnEDA inhibitors at 10 μM reduced suc-LLVY-
AMC hydrolysis by >95%, implying synergy between β2 and β5
inhibition of enzymatic activities. We determined the IC50s of our
compounds against Pf20S β5 in the presence of 0.5 μM WLW-VS
in enzymatic screens to block the confounding hydrolysis by β2
(Fig. 2F). We improved the selectivity indexes of AsnEDAs for
Pf20S versus human c-20S (Fig. 2F) from 28-fold for PKS21221 to
588-fold for PKS21224 and increased the IC50s against i-20S β5i by
280-fold (from 4 nM to 1,150 nM) with only an approximately
sixfold reduction in EC50s in a whole-cell assay. The IC50s of all
tested compounds correlated well with their respective EC50s
against P falciparum in vitro (SI Appendix, Fig. S3).
Activity Against the Asexual Erythrocytic Stage. We next determined
the EC50s of PKS21004 against established laboratory strains of P.
falciparum with different points of origin and with different drug-
resistance profiles (Fig. 3A). PKS21004 was potent against all lines
tested. EC50s ranged from 1.5 nM against P. falciparum V1S, a
multidrug-resistant South East Asian strain, to 10 nM against P.
falciparum HB3, a Central American strain resistant to pyrimeth-
amine. Five more recently isolated parasite strains from the Greater
Mekong subregion, two of which are artemisinin sensitive and three
of which are artemisinin resistant, showed a narrow range of EC50s
(1.5 nM–6 nM) to PKS21004. PKS21221, PKS21287, and PKS21224
also showed activity (SI Appendix, Fig. S4).
TDI4258 was further tested for ex vivo activity against P. fal-
ciparum samples from 38 malaria patients in Uganda. The EC50s
ranged from 11–81 nM, with a mean of 30 nM (Fig. 3B and SI
Appendix, Table S3), which is consistent with EC50s against the P.
falciparum laboratory strains. There was no detectable associa-
tion between sensitivities to TDI4258 and chloroquine among
the tested Ugandan isolates (SI Appendix, Table S3) (27).
To understand the dynamics of antimalarial action, we assessed
the in vitro killing profile of PKS21224. The in vitro parasite re-
duction ratio (PRR) assay directly measures the number of para-
sites that remain viable at different time points post drug exposure
(28). PKS21224 showed a P. falciparum killing profile similar to
that of pyrimethamine (log PRRs of 2.7 and 2.8, respectively) (Fig.
3C) with a lag phase (the time needed to observe the maximal
killing effects of the drug) of 24 h and a parasite clearance time
(the time needed to kill 99.9% of the initial population) of 61 h.
Activity Against P. falciparum Transmission and Mosquito Stages.We
tested activities of PKS21004, PKS21224, and PKS21287 against
stage III (Fig. 4A) and stage V P. falciparum gametocytes with
dihydroartemisinin (DHA) as a positive control (Fig. 4B). All
three compounds showed in vitro antigametocyte activity after
24, 48, and 72 h, with EC50s of 28, 140, and 212 nM, respectively.
Antigametocyte activity increased by 2.3- to 3.6-fold from 24 to
48 h (SI Appendix, Fig. S5 and Table S4) with little additional
enhancement of killing at 72 h. In comparison, the activity of
DHA did not improve with exposure longer than 24 h, consistent
with its rapid killing mechanism. Our compounds were also ef-
fective against mature stage V gametocytes at 72 h, with EC50s of
57 nM, 227 nM, and 229 nM for PKS21004, PKS21224, and
PKS21287, respectively (Fig. 4B).
PKS21224, PKS21287, and TDI4258 were further tested in a
gamete activation assay. The activation of male but not female
gametes was susceptible to inhibition of Pf20S β5, with EC50s of
140 nM–240 nM (Fig. 4C and SI Appendix, Table S5) (29).
The inability of male gametes to undergo activation would pre-
clude the generation of infectious sporozoites and block malaria
transmission.
Activity Against Hepatic-Stage Parasites. The activity of PKS21004
against preerythrocytic-stage parasites was tested using a P. berghei-
HepG2 model. Luciferase-expressing P. berghei sporozoites were
added to HepG2 cells in the presence or absence of PKS21004
(30). Infectivity was determined 48 h postinfection by quantifica-
tion of luciferase activity. PKS21004 demonstrated potent inhibition
of liver-stage development with an EC50 of 16.3 nM (Fig. 4D). Due
to the selectivity of our compounds, we were able to determine the
effect of proteasome inhibition directly on sporozoite-to-merosome
development before and after hepatic cell invasion. Our findings
Fig. 3. Erythrocytic stage and ex vivo activities and PRR of AsnEDAs. (A)
IC50s of PKS21004 against various strains of P. falciparum. (B) Ex vivo activity
of TDI4258 against 38 clinical samples of isolates from Uganda. The geo-
metric mean EC50 was calculated as 30 nM. (C) PRR of PKS21224. An in vitro
parasite reduction rate assay was used to determine onset of action and rate
of killing as described (28). P. falciparum was exposed to PKS21224 at a
concentration equivalent to 10× EC50. The number of viable parasites at each
time point was determined as described. Four independent serial dilutions
were done with each sample to correct for experimental variation; error bars
indicate SD. Previous results with current antimalarial drugs tested using the
same protocol are shown for comparison (28).
Fig. 4. Antimalarial activities of AsnEDAs against gametocyte stage, gam-
ete activation, and liver stage. (A and B) AsnEDAs and DHA as a positive
control were dose-dependently evaluated against gametocytes at stages III
(A) and V (B). (C) Inhibition of P. falciparum gamete activation. PKS21224,
PKS21287, and TDI4258 were dose-dependently evaluated in a dual gamete
activation assay. FG, female gametes; MG, male gametes. (D) Dose–response
curve of PKS21004s activity against P. berghei preerythrocytic stages in the
HepG2 model. Data shown are the average of three independent experi-
ments, each performed in triplicate.
E6866 | www.pnas.org/cgi/doi/10.1073/pnas.1806109115 Kirkman et al.
suggest that functional proteasomes are required for parasite
development within the hepatocyte.
Synergy Between DHA and Proteasome Inhibitors. Parasite protea-
some inhibition reportedly can reverse artemisinin resistance (5),
where artemisinin resistance is defined as slow clearance post
drug exposure as measured by a ring-stage survival assay (RSA)
(31). We tested TDI4258 in combination with DHA using a
modified ring-stage survival assay (RSA) with artemisinin-resistant
parasites that contain a mutant Kelch (R539T) protein in a
multidrug-resistant Dd2 strain background (32). We exposed early
1- to 3-h ring-stage parasites to a 3-h pulse of DHA and contin-
uous TDI4258 for 72 h, as described (5, 31). Parasitemia was
measured at 72 h post initial exposure. Isobologram analysis
demonstrated synergistic killing of artemisinin-resistant parasites
by the combination of TDI4258 and DHA (Fig. 5A). Wild-type
Dd2 parasites remained sensitive to DHA and thus could not be
assessed for synergy in this assay.
Synergistic in Vitro Activity Against P. falciparum of Proteasome
Inhibitors That Target β2 and β5 Pf20S Subunits. To test if the syn-
ergy we noted above between β2 and β5 inhibitors against Pf20S
pertained to intact parasites, we tested β5 inhibitors together with
various concentrations of WLW-VS against the erythrocytic stages
of P. falciparum as described (33) and determined the viability of
intraerythrocytic parasites at 72 h. PKS21004, TDI4258, and
bortezomib all gave fractional inhibition concentration (FIC)
values of ≤0.5, demonstrating a synergistic effect of simultaneous
inhibition of Pf20S β5 and β2 (Fig. 5C). This suggests that the
binding of a ligand to one subunit can affect the binding of an-
other ligand to a distal subunit of the Pf20S.
Next we tested combined inhibition of P20S β2 and β5 (in a
fixed ratio of TDI4258:WLW-VS of 4:1) in the presence of DHA
in a ring-stage survival assay with an artemisinin-resistant strain,
as described above. Potent synergy after 3 h exposure to the
compounds was evident when viability was assessed 72 h after
initial exposure (Fig. 5B).
In Vivo Antimalarial Activity. The in vivo efficacy of TDI4258 was
tested in a mouse model of Plasmodium yoelii infection. Female
CF1 mice were infected i.v. with 3 × 105 P. yoelii-parasitized
erythrocytes and were treated daily for 4 d beginning 1 d after
inoculation. TDI4258 (15 mg/kg), WLW-VS (60 mg/kg), and
WLW-VS (60 mg/kg) plus TDI4258 (15 mg/kg) were adminis-
tered i.p. in DMSO. Parasitemia was determined on day 5. The
experiment was performed twice, and the data were pooled (Fig.
5D). TDI4258 did not yield a statistically significant reduction in
parasitemia compared with DMSO (21.5% reduction, P = 0.16),
likely reflecting its short (30-min) half-life in the mouse (SI
Appendix, Table S2). WLW-VS reduced parasitemia by 42%
(P = 0.0014). The combination of TDI4258 and WLW-VS re-
duced parasitemia by 95% (P < 0.0001). Thus, the synergy ob-
served in vitro between inhibition of P20S β2 and β5 appeared to
manifest in vivo during murine P. yoelii infection.
Mechanism of Resistance. For additional target validation and to
explore potential mechanisms of resistance, we cultured the
Dd2 strain of P. falciparum parasites in gradually increasing
concentrations of PKS21004 from the initial EC50 of 4 nM to
192 nM. After 4 mo, we obtained a stably resistant parasite line.
We were not able to generate any resistant parasites using the
same protocol with 3D7-strain parasites. We cloned parasites
from the resistant Dd2 line and maintained two clonal lines, P.
falciparum Dd2-R1 and Dd2-R2. Both demonstrated ∼130-fold
resistance to PKS21004 (Fig. 6A). Resistance extended to other
members of the AsnEDA class; for example, both lines were 40-
fold more resistant to PKS21224 and 13-fold more resistant to
TDI4258 than unselected Dd2 parasites. However, resistance
was specific, in that there was little or no change in EC50s against
DHA, atovaquone, or piperaquine (Fig. 6A).
Intriguingly, the AsnEDA-resistant parasites did not demon-
strate resistance to another β5 inhibitor, bortezomib; on the con-
trary, they demonstrated a twofold increase in susceptibility to
bortezomib. Bortezomib is a dipeptide boronate that forms a re-
versible covalent boron–oxygen bond with the hydroxyl group of
the active site Thr1N and primarily targets the β5 subunit (34). Its
P1 Leu and P2 Phe side chains bind to S1 and S2 pockets, re-
spectively, and its pyrazinoyl moiety binds along the substrate-
binding groove (35). The mutation conferring resistance to the
AsnEDA β5 inhibitors slightly enhanced the action of a dipeptidyl
boronate with a different binding pose. Increased sensitivity was
also seen with carfilzomib, a peptide epoxyketone proteasome
inhibitor drug. Moreover, the AsnEDA-resistant parasites had 12-
to 14-fold increased sensitivity to the β2 inhibitor WLW-VS.
To gain insight into the mechanism of resistance, we se-
quenced the genomes of the parental Dd2 strain and the two
resistant clones, P. falciparum Dd2-R1 and Dd2-R2. Surprisingly,
Fig. 5. In vitro synergy of AsnEDA and DHA, between β5 and β2 inhibition
and in vivo enhancement of anti-P. yoelii activity in a mouse model of malarial
infection. (A) In vitro synergy of TDI4258 and DHA against artemisinin-resistant
P. falciparum Dd2 Kelch13R539T. (B) In vitro synergy between the combination
of TDI4258, WLW-VS, and DHA against artemisinin-resistant P. falciparum Dd2
Kelch13R539T. (C) FIC values were determined for pairs TDI4258/WLW-VS,
bortezomib/WLW-VS, and PKS21004/WLW-VS using a 72-h dual drug assay.
(D) In vivo activity against P. yoelii in female CF1 mice. The percentage of
parasitemia was calculated by microscopic analysis of Giemsa-stained blood
smear samples at 5 d postinfection. The experiments were repeated twice and
are shown by filled and open circles, respectively. Mean parasitemia and sta-
tistical significance were calculated using pooled data. A one-way ANOVA test
was used for statistical analysis; n = 4 mice per group.
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as summarized in SI Appendix, Table S6, both resistant clones
bear a G-to-A mutation in the gene encoding the β6 proteasome
subunit (PF3D7_0518300), leading to an A117D amino acid
change; no mutation was found in the target β5 subunit. Both
clonal lines also harbored mutations in PF3D7_0822400, a gene
of unknown function (SI Appendix, Table S6). One clone also
carried a mutation in PF3D7_0724700, which encodes another
protein of unknown function. There was no evidence of copy
number variation of any genes.
The β6 proteasome subunit has no proteolytic activity. A117 is
predicted to reside in an α-helix adjacent to a loop (Tyr152–
Cyc159), part of which forms a wall between the β5 S1 side
pocket (S1SP) and the β5 S3 pocket. A117 is closely opposed to
β6 Tyr150 and β6 Tyr158, whose side chains are only 3.4 and 3.7 Å
distant from A117, respectively (Fig. 6B). The A117D mutation
introduces a negatively charged side chain that is expected to clash
with these two tyrosines (Fig. 6B), forcing the loop to undergo
conformational changes that would alter the shape and polarity of
the S1SP and the S3 pocket in β5, directly affecting the binding of
PKS21004. In contrast, the A117D and accompanying conforma-
tional changes are distal to the binding sites of both bortezomib
and carfilzomib (Fig. 6C), potentially explaining why the mutant
was not resistant to both bortezomib and carfilzomib.
To confirm that the mutation affected the binding affinity of
PKS21004, we enriched mutant Pf20S(β6A117D) and conducted
subunit labeling experiments (Fig. 6D, Left). In agreement with
the shift in EC50, PKS21004’s potency in blocking the labeling of
Pf20S β5 in Pf20S(β6A117D) by MV151 was reduced compared
with its ability to block the labeling of the wild-type proteasome.
Conversely, the potency of WLW-VS in blocking the labeling of
Pf20Sβ2 by MV151 was greater in the mutant than in the wild
type (Fig. 6D, Right).
Drug resistance-mediating mutations may be accompanied by
loss of fitness (36). To test if the β6 A117D mutation imposed a
fitness cost, we performed a plaque assay comparing the Pf
Dd2 parent with the Pf Dd2 R1 parasite line and identified subtle
(37) but significant differences in growth rates under normal cul-
ture conditions, with the Pf Dd2 parent appearing to have more
robust growth than the resistant parasite line (SI Appendix, Fig.
S6). We then exposed intraerythrocytic P. falciparum to X-ray ir-
radiation at 50 and 100 Gy, which is likely to damage DNA and
protein, and measured the parasite’s ability to recover from this
Fig. 6. AsnEDA resistance. (A) EC50s for parental Dd2 and two clonal resistant parasite lines. Resistant parasites had increased sensitivity to the β2 inhibitor
WLW-VS and to the β5 inhibitors bortezomib and carfilzomib, with no change in EC50s of unrelated antimalarials. (B) Computational mutation of β6 A117 to
aspartate. A117 is surrounded by β6 Y150 and Y158 with the shortest distance of 3.5 Å and 3.8 Å between the side chain residue of A117/Y150 and A117/Y158,
respectively. With the mutation of A117D, both rotamers lead to a steric clash between the charged side chain of D117 with Y150 and with Y158, respectively
(highlighted in red). (C) Superimposition of Pf20S β5β6 with PKS21004 (Left) and with bortezomib (BTZ) and carfilzomib (CFZ) (Right). The A117D mutation
forces conformational changes in the S1SP and S3 pockets, with which PKS21004 interacts, whereas bortezomib and carfilzomib do not interact. (D) Inhibition
of Pf20S (Upper) and Pf20S(β6A117D) (Lower) by PKS21004 (Left) and WLW-VS (Right), assessed by MV151. (E) Trophozoite-stage cultures at 0.5% parasitemia
were irradiated at 50 and 100 Gy. (Left) Parasite growth was monitored daily. A representative experiment done in triplicate is shown. (Right) R1 parasites
irradiated with 50 or 100 Gy took 4.3 and 16.7 d to recover growth, respectively, compared with Dd2 that took 1.3 and 6.8 d, respectively. The data are the
means from two independent experiments, each performed in triplicate.
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stress by monitoring the recovery of parasitemia to 2% (Fig. 6E,
Left) (38). Pf Dd2 recovered by days 1.3 (after 50 Gy) and 6.8
(after 100 Gy), whereas PfDd2 R1 recovered by days 4.3 (50 Gy)
and 16.7 (100 Gy) (Fig. 6E, Right), demonstrating a defect in the
ability of the resistant parasite line to withstand radiation stress.
Discussion
The spread of drug-resistant parasites is a major obstacle to the
WHO’s goal of reducing morbidity and mortality attributable to
malaria by 90% by 2030. Here we present a set of compounds
that spare both human constitutive and immuno-proteasomes
and target the malaria parasite proteasome. The proteasome is a
key regulator of the parasite’s ability to proliferate and adapt to
stress, likely including stresses imposed by artemisinin antimalarials
(5). We show that simultaneously targeting two different catalytic
proteasome subunits provides synergistic killing of P. falciparum as
well as synergism with artemisinin against artemisinin-resistant
parasites. Moreover, a mutation in the parasite proteasome that
confers resistance to blockade of one subunit can lead to increased
sensitivity to blockade of another. These results suggest that, despite
the conservation of proteasomes among eukaryotes, targeting P.
falciparum proteasome subunits offers a more promising approach
for antimalarial chemotherapy than was previously apparent.
We determined the activity of the AsnEDAs at multiple stages
of the malaria lifecycle. Activity against the gametocyte stage has
previously been determined only with nonselective inhibitors.
Here we found that the relatively selective AsnEDAs were ef-
fective against stage III and stage V gametocytes, the stage
poised for transmission to the mosquito. The AsnEDAs also
blocked male gamete activation, supporting the idea that pro-
teasome inhibitors can act as transmission-blocking antimalarials
at several stages. Our studies on the liver stage are unique in that
the species-selective nature of the compounds allowed us to treat
intrahepatic parasites for a prolonged time without toxicity to the
host cell. The efficacy of AsnEDAs at the preerythrocytic stage
indicates the potential use of proteasome inhibitors for malaria
prevention. This observation opens the door to study the biology
of the parasite proteasome in this important stage, which is as-
sociated with extensive parasite remodeling (30).
The availability of cryo-EM structures (17) to guide modeling
studies helped us better understand and improve the selectivity of
inhibitors for the P. falciparum proteasome against both the hu-
man constitutive proteasome and immunoproteasome. Expression
of human c-20S is ubiquitous, while i-20S is expressed pre-
dominantly in immune cells and proportionately more so when
they are stimulated with IFN-γ. The immunoproteasome plays
important roles in the activation of immune cells and in immune
surveillance. Selectivity for the pathogen’s proteasome is crucial
for proteasome inhibitors to advance as antiinfective agents.
Resistance to AsnEDA β5 inhibitors emerged in vitro only
after prolonged in vitro selection in one of two P. falciparum
lines tested. The resistance was associated with a mutation not in
the target β5 subunit but in the adjacent β6 noncatalytic struc-
tural subunit. Modeling studies suggest that the amino acid
change in β6 may alter the S1SP and S3 pockets formed by
β5 and β6. This demonstrates that a mutation in the β6 subunit
confers resistance to Pf20S β5 inhibitors by affecting distal region
of the substrate binding cleft. Similarly, a single amino acid
mutation in the trypanosomal proteasome nonproteolytic β4
subunit conferred resistance to a newly identified kinetoplastid-
specific proteasome inhibitor (20). The additional mutation
in PF3D7_0822400, a conserved protein with no known func-
tion, may contribute to resistance to proteasome inhibitors; a
supportive or adaptive role for this mutation has yet to be
explored.
The efficacy of AsnEDAs and WLW-VS with cultured para-
sites and in murine malaria infection suggests that combination
therapy with inhibitors of both the Plasmodium Pf20S β5 and
β2 subunits could offer an effective therapy for malaria, provided
that ongoing medicinal chemistry efforts lead to improved oral
bioavailability. Targeting both these subunits was synergistic
against purified proteasomes, erythrocytic-stage parasites in
vitro, and erythrocytic-stage parasites in the mouse. Similarly,
enhanced cytotoxicity from combined inhibition of the β2 and
β5 subunits has been described in human tumor cells (39, 40).
The findings reported here provide a biologic rationale for me-
dicinal chemistry campaigns directed at both subunits and sug-
gest that it will be fruitful to consider each set of inhibitors in the
context of its interaction with others. In addition, given that re-
sistance to a β5 inhibitor led to increased sensitivity to a
β2 inhibitor both in enzymatic studies and in vitro culture, dual
inhibition appears to lead to a highly desirable resistance-
thwarting strategy, collateral sensitivity (41). Further structural
studies with wild-type and A117D-mutant strains of Pf20S, with
and without inhibitors, should shed light on the mechanism
driving the increased sensitivity to WLW-VS observed in
PKS21004-resistant parasites.
A fitness cost that accompanies the development of drug re-
sistance has been described for various microorganisms, includ-
ing P. falciparum, and can help limit the spread of drug-resistant
parasites. Similarly, yeast bearing mutations associated with
bortezomib resistance grew more slowly than wild type, espe-
cially under stress conditions (42). The majority of mutations
reported to confer resistance to proteasome inhibitors in yeast or
cancer cells are in β5, in contrast to the β6 mutation we identified
in each of two resistant lines of P. falciparum.
The present findings strengthen the case for targeting the parasite
proteasome in antimalarial drug development. The inhibitors de-
scribed demonstrate the potential to inhibit the P. falciparum pro-
teasome while sparing not only the human constitutive proteasome
but also the human immunoproteasome. Further, they show that
inhibition of the P. falciparum β5 subunit can kill or block parasite
development in all stages of the parasite lifecycle—in the asexual
blood stage, during hepatic invasion and development, and in the
development and activation of gametocytes—offering the potential
for chemoprevention (by killing liver stages) and transmission
blocking (by inhibiting gametocytes and gamete activation), stages
for which there are few active antimalarials. Finally, these com-
pounds revealed the synergistic potential of exploiting long-range
interactions between distinct proteolytic subunits of Pf20S as well as
the opportunity for collateral sensitivity. Further development of
parasite proteasome inhibitors will be aided by a deeper un-
derstanding of the complex relationships among the proteasome
subunits. Such an understanding may be translated clinically to
maximize potency and raise the barrier to the development
of resistance.
Materials and Methods
The SI Appendix, SI Methods details materials and methods for P. falciparum
cultivation; Pf20S enrichment; biochemical characterization of Pf20S; IC50 de-
terminations against c-20S, i-20S, and Pf20S; dose–response studies against
parasites in erythrocytic, preerythrocytic, and gametocyte asexual stages and
against gamete activation; selection of resistant mutants; active subunit la-
beling; PRR assay; efficacy studies in mice; molecular modeling; assays for
synergy, plaque formation, and recovery from irradiation; chemical synthesis;
and characterization of compounds. In vivo efficacy studies were performed
with the approval of the Portland Veterans Administration Medical Center
Institutional Animal Care and Use Committee. The relevant clinical trials and
analyses of cultured parasites were approved by the Uganda National Council
of Science and Technology, the Makerere University Research and Ethics
Committee, and the University of California, San Francisco Committee
on Human Research. Informed consent was obtained from the blood
sample donors.
ACKNOWLEDGMENTS. We thank Takeda Pharmaceuticals, Inc. for providing
pharmacokinetic analyses and GlaxoSmithKline’s Diseases of the Developing
World campus at Tres Cantos, Spain for providing gamete activation and
pharmacokinetic assays as gifts-in-kind; Dr. Takafumi Yukawa, Dr. Akinori
Kirkman et al. PNAS | vol. 115 | no. 29 | E6869
M
IC
RO
BI
O
LO
G
Y
Toita, Mr. Tzu-Tshin Wong, Dr. John Ginn, Dr. Andrew Stamford, and
Dr. Peter Meinke at Tri-Institutional Therapeutics Discovery for medicinal
chemistry discussions; Dr. J. David Warren at The Abby and Howard P. Milstein
Synthetic Chemistry Core Facility at Weill Cornell Medicine for assistance;
Dr. Hao Li and Dr. Matthew Bogyo for advice and sharing reagents;
Ms. Stephanie A. Rasmussen (Dominican University) and Amanda Chan
(Weill Cornell Medicine) for technical assistance; Jamie Bean (Memorial
Sloan Kettering Cancer Center, MSKCC) for assistance with whole-genome
sequencing; Dr. Angelika Sturm, Dr. Koen Dechering, and Mr Rob Henderson
at TropIQ Health Sciences for providing parasite biomass; and Dr. Katja
Becker at Justus Liebig University Giessen for sharing reagents. This work
was supported by NIH Grants 1R21AI123794 (to G.L. and L.A.K.), R21
AI101393 (to G.L.), 1R21AI094167 (to P.B.), AI075045 (to P.J.R. and R.A.C.),
and T37MD003407 (to L.F.G. and D.J.M.); National Science Foundation Grant
IOS-1146221 (to P.B.); the Department of Medicine, Weill Cornell Medicine
Seed Fund (L.A.K.); the Tri-Institutional Therapeutics Discovery Institute and
Weill Cornell Medicine Matching Fund (G.L.); Medicines for Malaria Venture
RD/15/0001 (R.A.C. and P.J.R.); and United States Department of Veterans
Affairs Biomedical Laboratory Research and Development Grant BX002440
(to J.S.D.). We acknowledge the use of the Integrated Genomics Operation
Core at MSKCC, funded by the National Cancer Institute Cancer Center Sup-
port Grant P30 CA08748, Cycle for Survival, and the Marie-Josée and Henry R.
Kravis Center for Molecular Oncology (MSKCC). The Department of Microbi-
ology and Immunology at Weill Cornell Medicine is supported by the William
Randolph Hearst Trust. L.A.K. is a Hearst Clinical Scholar.
1. WHO (2016) World Malaria Report 2016 (WHO, Geneva).
2. Ariey F, et al. (2014) A molecular marker of artemisinin-resistant Plasmodium falci-
parum malaria. Nature 505:50–55.
3. Mbengue A, et al. (2015) A molecular mechanism of artemisinin resistance in Plas-
modium falciparum malaria. Nature 520:683–687.
4. Imwong M, Hien TT, Thuy-Nhien NT, Dondorp AM, White NJ (2017) Spread of a single
multidrug resistant malaria parasite lineage (PfPailin) to Vietnam. Lancet Infect Dis
17:1022–1023.
5. Dogovski C, et al. (2015) Targeting the cell stress response of Plasmodium falciparum
to overcome artemisinin resistance. PLoS Biol 13:e1002132.
6. Li H, et al. (2016) Structure- and function-based design of Plasmodium-selective
proteasome inhibitors. Nature 530:233–236.
7. Li H, et al. (2014) Assessing subunit dependency of the Plasmodium proteasome using
small molecule inhibitors and active site probes. ACS Chem Biol 9:1869–1876.
8. Li H, et al. (2014) Identification of potent and selective non-covalent inhibitors of the
Plasmodium falciparum proteasome. J Am Chem Soc 136:13562–13565.
9. Li H, et al. (2012) Validation of the proteasome as a therapeutic target in Plasmodium
using an epoxyketone inhibitor with parasite-specific toxicity. Chem Biol 19:
1535–1545.
10. LaMonte GM, et al. (2017) Development of a potent inhibitor of the Plasmodium
proteasome with reduced mammalian toxicity. J Med Chem 60:6721–6732.
11. Gantt SM, et al. (1998) Proteasome inhibitors block development of Plasmodium spp.
Antimicrob Agents Chemother 42:2731–2738.
12. Lindenthal C, Weich N, Chia YS, Heussler V, Klinkert MQ (2005) The proteasome in-
hibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium
parasites. Parasitology 131:37–44.
13. Kreidenweiss A, Kremsner PG, Mordmüller B (2008) Comprehensive study of pro-
teasome inhibitors against Plasmodium falciparum laboratory strains and field iso-
lates from Gabon. Malar J 7:187.
14. Czesny B, Goshu S, Cook JL, Williamson KC (2009) The proteasome inhibitor epox-
omicin has potent Plasmodium falciparum gametocytocidal activity. Antimicrob
Agents Chemother 53:4080–4085.
15. Aminake MN, et al. (2011) Thiostrepton and derivatives exhibit antimalarial and
gametocytocidal activity by dually targeting parasite proteasome and apicoplast.
Antimicrob Agents Chemother 55:1338–1348.
16. Muchamuel T, et al. (2009) A selective inhibitor of the immunoproteasome subunit
LMP7 blocks cytokine production and attenuates progression of experimental ar-
thritis. Nat Med 15:781–787.
17. Santos RLA, et al. (2017) Structure of human immunoproteasome with a reversible
and noncompetitive inhibitor that selectively inhibits activated lymphocytes. Nat
Commun 8:1692.
18. Lin G, et al. (2009) Inhibitors selective for mycobacterial versus human proteasomes.
Nature 461:621–626.
19. Lin G, et al. (2013) N,C-Capped dipeptides with selectivity for mycobacterial protea-
some over human proteasomes: Role of S3 and S1 binding pockets. J Am Chem Soc
135:9968–9971.
20. Khare S, et al. (2016) Proteasome inhibition for treatment of leishmaniasis, Chagas
disease and sleeping sickness. Nature 537:229–233.
21. Hsu HC, et al. (2017) Structural basis for the species-selective binding of N,C-capped
dipeptides to the Mycobacterium tuberculosis proteasome. Biochemistry 56:324–333.
22. Sula Karreci E, et al. (2016) Brief treatment with a highly selective immunoproteasome
inhibitor promotes long-term cardiac allograft acceptance in mice. Proc Natl Acad
Sci USA 113:E8425–E8432.
23. Singh PK, et al. (2016) Immunoproteasome beta5i-selective dipeptidomimetic inhib-
itors. ChemMedChem 11:2127–2131.
24. Fan H, Angelo NG, Warren JD, Nathan CF, Lin G (2014) Oxathiazolones selectively
inhibit the human immunoproteasome over the donstitutive proteasome. ACS Med
Chem Lett 5:405–410.
25. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M (2004) Simple and in-
expensive fluorescence-based technique for high-throughput antimalarial drug
screening. Antimicrob Agents Chemother 48:1803–1806.
26. Verdoes M, et al. (2006) A fluorescent broad-spectrum proteasome inhibitor for la-
beling proteasomes in vitro and in vivo. Chem Biol 13:1217–1226.
27. Rasmussen SA, et al. (2017) Changing antimalarial drug sensitivities in Uganda.
Antimicrob Agents Chemother 61:e01516-17.
28. Sanz LM, et al. (2012) P. falciparum in vitro killing rates allow to discriminate between
different antimalarial mode-of-action. PLoS One 7:e30949.
29. Miguel-Blanco C, et al. (2017) Hundreds of dual-stage antimalarial molecules dis-
covered by a functional gametocyte screen. Nat Commun 8:15160.
30. Govindasamy K, et al. (2016) Invasion of hepatocytes by Plasmodium sporozoites
requires cGMP-dependent protein kinase and calcium dependent protein kinase 4.
Mol Microbiol 102:349–363.
31. Witkowski B, et al. (2013) Novel phenotypic assays for the detection of artemisinin-
resistant Plasmodium falciparum malaria in Cambodia: In-vitro and ex-vivo drug-
response studies. Lancet Infect Dis 13:1043–1049.
32. Straimer J, et al. (2015) Drug resistance. K13-propeller mutations confer artemisinin
resistance in Plasmodium falciparum clinical isolates. Science 347:428–431.
33. Gorka AP, Jacobs LM, Roepe PD (2013) Cytostatic versus cytocidal profiling of quin-
oline drug combinations via modified fixed-ratio isobologram analysis. Malar J 12:
332.
34. Groll M, Berkers CR, Ploegh HL, Ovaa H (2006) Crystal structure of the boronic acid-
based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.
Structure 14:451–456.
35. Schrader J, et al. (2016) The inhibition mechanism of human 20S proteasomes enables
next-generation inhibitor design. Science 353:594–598.
36. Rosenthal PJ (2013) The interplay between drug resistance and fitness in malaria
parasites. Mol Microbiol 89:1025–1038.
37. Thomas JA, et al. (2016) Development and application of a simple plaque assay for
the human malaria parasite Plasmodium falciparum. PLoS One 11:e0157873.
38. Calhoun SF, et al. (2017) Chromosome end repair and genome stability in Plasmodium
falciparum. MBio 8:e00547-17.
39. Weyburne ES, et al. (2017) Inhibition of the proteasome beta2 site sensitizes triple-
negative breast cancer cells to beta5 inhibitors and suppresses Nrf1 activation. Cell
Chem Biol 24:218–230.
40. Kraus M, et al. (2015) The novel β2-selective proteasome inhibitor LU-102 synergizes
with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of
myeloma cells. Haematologica 100:1350–1360.
41. Baym M, Stone LK, Kishony R (2016) Multidrug evolutionary strategies to reverse
antibiotic resistance. Science 351:aad3292.
42. Huber EM, Heinemeyer W, Groll M (2015) Bortezomib-resistant mutant proteasomes:
Structural and biochemical evaluation with carfilzomib and ONX 0914. Structure 23:
407–417.
E6870 | www.pnas.org/cgi/doi/10.1073/pnas.1806109115 Kirkman et al.
